Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study

Abstract Background Rivaroxaban could be an attractive alternative to low molecular weight heparin for the treatment of cancer‐associated venous thromboembolism (VTE) but the safety and effectiveness remain unclear. We examined risk of recurrent VTE and major bleeding associated with rivaroxaban tre...

Full description

Saved in:
Bibliographic Details
Main Authors: Mette Søgaard, Peter Brønnum Nielsen, Flemming Skjøth, Jette Nordstrøm Kjældgaard, Torben Bjerregaard Larsen
Format: Article
Language:English
Published: Wiley 2019-03-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.1997
Tags: Add Tag
No Tags, Be the first to tag this record!